Research programme: farnesoid-X-activated receptor agonists - Akarna Therapeutics

Drug Profile

Research programme: farnesoid-X-activated receptor agonists - Akarna Therapeutics

Alternative Names: AKN 083

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Akarna Therapeutics
  • Class Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 20 Sep 2016 Akarna Therapeutics has been acquired by Allergan
  • 22 Feb 2016 Akarna Therapeutics plans clinical trials for farnesoid-X-activated receptor agonist (Akarna Therapeutics website, February 2016)
  • 16 Feb 2016 Preclinical trials in Non-alcoholic steatohepatitis in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top